GenoMethods exists to help readers understand biotechnology through clear, source-based and editorially responsible publishing.
Our editorial map follows: Method → Medicine → Market. This framework reflects the way biotechnology develops: a method or platform creates new technical possibilities, those possibilities may move into medical development, and scientific and clinical progress influences companies and markets.
Coverage Pillars
Method
This pillar covers the scientific and technical systems used to understand, measure, modify or engineer biology.
- bioengineering;
- genomics and sequencing;
- bioinformatics;
- computational biology;
- AI in biology;
- experimental platforms and research technologies.
The reader value is understanding how a method works, how it was validated, what it can do, how it compares with existing approaches and what limitations remain.
Medicine
This pillar covers how biotechnology moves into drug development, clinical trials, diagnostics and advanced therapies.
- drug discovery;
- clinical trials;
- genome editing;
- gene therapy;
- cell therapy;
- diagnostics and biomarkers;
- precision medicine.
The reader value is understanding what the evidence means clinically, what stage of development has actually been reached and what the available evidence still does not establish.
Market
This pillar covers biotechnology companies and the commercial structures around scientific and clinical assets.
- company strategy and pipelines;
- licensing;
- M&A;
- financing;
- strategic partnerships;
- biotechnology markets.
The reader value is understanding how commercial decisions connect to underlying science, clinical evidence, development responsibilities and the actual economics disclosed in biotechnology transactions.
What We Do Not Cover
Clear topical boundaries help GenoMethods maintain biotechnology focus rather than expanding into unrelated general-interest publishing.
- general technology news without meaningful biotechnology relevance;
- general AI news unrelated to biology;
- generic personal-finance or stock-market coverage;
- general wellness and lifestyle content;
- unsupported scientific, medical or financial claims;
- fake reviews or testimonials;
- unsupported rankings;
- guaranteed medical, financial or commercial outcomes;
- commercial material disguised as independent editorial coverage.
Audience
GenoMethods serves readers who need biotechnology context beyond a headline or company announcement and who benefit from seeing the relationship between methods, evidence, clinical development and markets.
- biotechnology and life-science professionals;
- researchers and scientifically engaged readers;
- genomics, bioinformatics and computational biology professionals;
- drug-development and clinical-development professionals;
- biotechnology company operators;
- biotechnology-focused investors and market observers;
- regulatory, policy and industry observers.
Story Prioritization
GenoMethods cannot cover every biotechnology announcement. Stories receive greater priority when the publication can add useful evidence, context or explanation.
- are directly relevant to biotechnology;
- are useful to readers;
- are timely;
- can be supported by reliable sources;
- explain a complex topic clearly;
- correct a common misunderstanding;
- have meaningful scientific, clinical, regulatory or commercial significance.
Geographic Scope
The United States is the primary market for GenoMethods.
Relevant developments from the United Kingdom, European Union, Switzerland, Canada, Australia, Singapore, China and the wider Asia-Pacific region may also be covered when they matter to the publication's biotechnology focus.
International coverage is based on editorial relevance rather than an attempt to report every biotechnology event in every geography.
Historical Note
GenoMethods was founded in 2002 and continues to focus on biotechnology and the methods used to understand, engineer and translate biological systems.
Professional Information Boundary
GenoMethods content is informational and does not provide personalized medical, legal, financial, tax, investment, mental health or other professional advice.
Reporting on a therapy, company, clinical result or transaction should not be interpreted as individualized guidance for a reader's personal circumstances.
Reader Input
Editorial suggestions: editorial@genomethods.org
General contact: livelong@genomethods.org
Related Pages
1 Broadway
Cambridge, MA 02142
United States